728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Value Added Services in Cardiometabolic Diseases — Payer views

LONDON, Nov. 28, 2017 /PRNewswire/ — Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder there is a widespread cynical view among payers that many “beyond the pill” support services are little more than a marketing ploy. How can Pharma get back on track and deliver sustained VAS that innovatively support long-term cardiometabolic disease patients, change behaviour and build trust with payers? Value-added Services in Cardiometabolic Diseases meets head-on the current criticism of many VAS initiatives, and through the hard-hitting insights of senior US and EU payers, clearly identifies the key VAS design, development and areas for improvement that industry needs to address.

Download the full report: https://www.reportbuyer.com/product/5214611

Answering key questions:

Reasons to buy this report
VAS have become a standard feature of pharma’s outreach and companies can point to a raft of monitoring, education and health support services that have made a real impact. So why are payers sceptical and how is that impacting pharma’s prospects? Short lived VAS are not building trust with payers or fully meeting the long-term needs of patients – especially in chronic conditions such as diabetes. It can be better. In this report experienced US and EU payers identify what good, on-target VAS look like, how working with payers can lead to better VAS solutions and how sharing outcomes data can help prove product value to a company’s commercial benefit.

This report will enable you to:
• Plan VAS into the product lifecycle to support patients with chronic cardiometabolic diseases
• Leverage real world VAS outcomes data to support value claims with payers
• Work collaboratively with payers to design innovative VAS programmes
• Learn why working with trusted independent 3rd parties to deliver VAS will gain payer approval
• Innovate to address non-adherence in a patient-centric way
• Understand how US and EU5 payers’ views of VAS vary and nuance your programmes to meet local conditions

Download the full report: https://www.reportbuyer.com/product/5214611

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *